



(51) International Patent Classification:

A61K 31/327 (2006.01) A61K 33/24 (2006.01)  
A61K 31/32 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2015/062538

(22) International Filing Date:

24 November 2015 (24.11.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/085,235 26 November 2014 (26.11.2014) US

(72) Inventor; and

(71) Applicant : YU, Baofa [CN/US]; 4443 Governor Dr., San Diego, CA 92122 (US).

(74) Agent: CHRISTENSEN, Michael, R.; Knobbe, Martens, Olson & Bear, LLP, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US).

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:

— with international search report (Art. 21(3))

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

(54) Title: HAPTEN-ENHANCED CHEMOIMMUNOTHERAPY BY ULTRA-MINIMUM INCISION PERSONALIZED INTRATUMORAL CHEMOIMMUNOTHERAPY

Figure 1



(57) Abstract: Embodiments disclosed herein provide methods for treating neoplasm in a mammal, comprising intratumorally administering to the neoplasm an effective amount of a pharmaceutical composition comprising: a hapten; and a redox agent, whereby the neoplasm is treated.